



**EORTC**  
European Organization for Research  
and Treatment of Cancer

# **Development of an EORTC quality of life module for G.I.-related Neuroendocrine Tumours: UPDATE**

Dr. J Ramage, MD FRCP. Consultant Physician in  
Gastroenterology and Hepatology  
Liz Friend, Clinical Trials Co-ordinator  
Barbara King, Specialist Research Nurse

24<sup>th</sup> April 2008 Stockholm Sweden

# AIMS

- To test the scale structure, reliability and validity of the gastrointestinal NET module (QLQ-G.I.NET21)
- To develop a questionnaire which will determine if treatment are having an effect on QOL for patients with specific to G.I. neuroendocrine tumours

# Phase 4

- Each patient will undergo 3 assessments, pre treatment and then month 3 and 6 post treatment
- 80 patients will be involved in test-retest two weeks after the 6 month assessment
- Liverpool and Basingstoke

# Phase 4

- 400 patients needed over the next 3 years
- 11 active sites
- 4 sites no patients recruited yet
- 3 sites awaiting ethical approval
- 3-4 new sites waiting to start
- Danish site shown interest

# Recruitment To Date

- 109 patients have been recruited as of 23<sup>rd</sup> of April 2008
- Payment of 200 euros made once the first 10 patients are enrolled
- Recruitment deadlines will need to be extended

# Recruitment

## European Site

- Poland – Krzysztof Jeziorski-23 patients
- Sweden- Gunnel Larsson-15 patients
- Germany- Jessica Rademacher- 10patients
- Spain- Dr Diaz- 8 patients
- Netherlands- Baabs Taal- 6 patients
- Italy- Olimpia Pino- 5 patients

# Recruitment

## UK Sites

- Basingstoke- 17 patients
- Liverpool- 15 patients
- Kings College- 6 patients
- Royal Free- 1 patient
- Southampton- 2 patient
- Hampshire Clinic- 1 patient

# Patient Groups

- 3 Treatment Groups
- Group 1 Somatostatin analogues or Interferon treatment – 51 patients
- Group 2 Radionuclide therapy or chemotherapy treatment – 23 pts
- Group 3 Ablative Therapies and Liver surgery – 9 patients
- Polish sites not included in this table

# Validity

- Correlation Analyses ie social function of C30 will correlate with social scale of G.I.NET
- Group Comparisons ie Karnofsky performance status at time of assessment and disease stage
- Responsiveness to Clinical Change ie improvement or deterioration in health status

# Time Scale

- All patients asked at 6 month follow up  
“Which would be the best time scale to use in this questionnaire – is it 1 week, 4 weeks or no preference?”
- Please make sure that this question is asked

# Summary

- PLEASE send any patient information to me on FAX +44 1256 360415
- If I don't have you enrolled patients on the data base then we think you don't have any patients
- Any problems or issues?
- Any new sites?